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INTRODUCTION
Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental condition affecting around 5% of children. (1) Longitudinal follow-up studies show that ADHD frequently persists into adulthood, either as the full blown disorder, or as persistent subthreshold levels of symptoms causing impairment, (2, 3) with epidemiological surveys suggesting an estimated prevalence in adults of around 3-4%. (4) Although inattention, hyperactivity and impulsivity are considered to be the core symptoms of ADHD, (5) emotional lability (EL), characterised by low frustration tolerance, irritability and mood lability, is a commonly associated feature that causes considerable distress to individuals and their families. (6) Clinically significant levels of EL are present in around 70-90% of adults with ADHD, and is an independent predictor of functional impairments beyond those accounted for by inattention and hyperactivity-impulsivity. (7) (8) (9) (10) The importance of EL in adult ADHD was established by Wood, Wender and colleagues, who were among the first to describe the syndrome and included affective lability, hot temper, and stress intolerance as core symptoms of the disorder. (11, 12) The current diagnostic and statistical manual of mental disorders (DSM-5) describes such emotional symptoms as associated features of ADHD that support the diagnosis. (13) Furthermore, high levels of EL are also observed in ADHD patients who do not present with co-occurring mental health disorders, (7) indicating that the association of EL with ADHD cannot always be accounted for by the presence of comorbid disorders such as bipolar or borderline personality disorders. (14) Debate as to whether EL reflects a core domain of ADHD in adults is ongoing. (5, 15, 16) In particular it is unclear whether medications such as stimulants and atomoxetine, used in the treatment of ADHD, also lead to reductions in EL. Randomized placebo controlled trials in adults with ADHD conclusively show that both groups of medications lead to clinically significant reductions in symptoms of ADHD symptoms. (9, (17) (18) (19) (20) However, the effects of drugs used to treat ADHD on EL are yet to be established.
In order to assess the effects of stimulants and atomoxetine on EL in adults we conducted a systematic review and meta-analysis of randomised placebo-controlled trials. Our primary aim was to quantify the effects of stimulants and atomoxetine on EL. Our secondary aim was to contrast the effects of stimulants and atomoxetine on EL with the effects on the core ADHD symptoms of inattention and hyperactivity-impulsivity in the same studies.
METHODS
We conducted a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. (21) 
Search strategy and selection criteria
Studies were included if: (a) they were randomised double-blind placebo-controlled trials of stimulants or atomoxetine; (b) participants were adults aged 18-60 years with any mental health diagnosis associated with EL 1 ; (c) the study measured at least one outcome of behavioural change related to EL; (d) for each outcome measure, mean (M) and standard deviation (SD) from baseline and follow-up for the placebo and active group were reported or obtained upon contacting the authors. Trials published in languages other than English were excluded for feasibility reasons of translation.
A literature search was conducted using pre-specified search terms (see table 1 in appendix 1) using the following databases: Embase (1974 to 2015 June 10th), PsychInfo (1806 to June week 2, 2015) and Ovid Medline® (1946 to June week 1, 2015) . Unpublished or ongoing trials were searched on the clinicaltrials.gov website. Authors were contacted to request missing data. In spite of the official systematic search being stopped in June 2015, there were no new clinical trials published meeting the selection criteria of this systematic review up until 2 nd May, 2017.
To assess for the risk of bias, study quality was assessed by two independent authors (TRM & PM) according to PRISMA guidelines and the Cochrane Handbook of Systematic Reviews (22) (see table 2 and 3 in appendix 1). TRM and PM then met to discuss assessments and reach a consensus on study inclusion. Unresolved classification of studies was arbitrated by PA and REC. Studies were classified overall as unclear, low or high risk. High risk studies were excluded. Data extraction was performed by TRM and checked by two research assistants. The main outcome measures were raw scores of mean and standard deviation of the pre-and posttreatment measures of EL and DSM-IV ADHD symptoms for active and placebo arms. Intent to treat analysis (ITT) was reported. For trials with a cross-over design, only the initial precross-over data was included, if available, and treated as a parallel group trial. We used this rather conservative approach because there was lack of sufficient data to permit analysis of within-individual change (i.e. correlations of scores between conditions were not given). Missing data that remained unavailable after contacting authors were not imputed.
Outcome measures
Two outcome domains were included in the meta-analysis: EL and DSM-IV ADHD symptoms. EL was measured using the emotion dysregulation subscale of the Wender Reimherr Adult Attention Deficit Disorder Scale (WRAADDS-EDS) (11) , which combined subscales of hot temper, affective lability and emotional over-reactivity, or the emotion control subscale of the Behaviour Rating Inventory of Executive Function (BRIEF-A). (23) ADHD DSM-IV domains were measured by the investigator-rated, self-rated or informantrated Conners Adult ADHD Rating Scale (CAARS) (24) , ADHD-Rating Scale (ADHD-RS) or the investigator rated WRAADDS. (11) Table 4 (in appendix 1) contains a detailed list of measures used in these two domains.
Data analysis

Statistical analyses:
Analyses were performed in STATA 11.2. (25) An initial analysis in the full sample across the two domains of EL and ADHD symptoms was run, following this, subgroup analyses (see below) were conducted.
We report the SMD calculated as the mean pre-to-post-treatment change, minus the mean pre-to-post-placebo group change, divided by the pooled pre-test standard deviation (SD), with a bias adjustment. The equation for this method is presented below. (26) Effects sizes were classified according to Cohen's d as follow: d= 0.2, d= 0.5 and d= 0.8 as small, medium and large respectively. (27) Given the between-study heterogeneity in terms of study design, trial duration, outcome measures and participant characteristics we chose apriori to use random-effects models. (28) A nominal level of significance was set at p < .05. The I 2 statistic assessed heterogeneity between studies. Publication bias was investigated on the basis of funnel plots using Begg & Mazumdar's rank correlation approach and the Egger regression asymmetry test.
Subgroup analyses:
Additional analyses were conducted in subsets of the total sample to investigate the stability of the results to the scale used to measure EL (WRAADS-EDS versus BRIEF-A) and the class of study medication (stimulants versus atomoxetine).
2.3.2.1
Outcome measure: EL was measured by either BRIEF-A the emotion control subscale (23) or the WRAADDS-EDS. (11) Analyses were performed separately on the trials using the BRIEF-A (n=3) and WRAADDS-EDS (n=6).
Medication class:
Included trials medicated participants with either stimulants or atomoxetine. Analyses were conducted separately on studies which used stimulants (n=6) and atomoxetine (n=3).
Medication class and outcome measure:
To check whether the medication gave different effect size estimates when controlling for the EL scale (BRIEF-A or WRAADDS-EDS) used: we compared the effects of stimulants set against atomoxetine, first when EL was measured by the WRAADDS-EDS and then when it was measured by the BRIEF-A.
RESULTS
Selection of studies
The initial database search identified 3864 unique publications. 403 abstracts were screened against the inclusion criteria, of which 385 were excluded because: the data were already used or reported in another publication (n=18); the outcomes were unsuitable (n=44); the studies were not randomised controlled trials (n=61), failed to report a placebo group (n=4); were open label trials (n=5); used unsuitable medication (medications other than stimulants or atomoxetine) (n=14) or population (n=6); were not published in English (n=5); requests for data from unpublished trials were not returned successfully (n=24); or the trial was conducted on children (n=204). Eighteen full-text articles were subsequently quality appraised and eight were excluded because of: an open label design (n=1), unsuitable population (n=2), unsuitable design (n=2) and unsuitable outcome (n=3). Ten studies met the inclusion criteria, but one of these had to be excluded on the grounds of missing statistics, leaving nine studies for inclusion in the final pool for the meta-analysis (see fig. 1 and tables 5, 6 and 7 in appendix 1). 
Quality and characteristics of studies included in qualitative synthesis
Nine studies were judged to be of sufficient quality and suitability to be included in the quantitative synthesis (see supplementary tables 2 and 3). Randomisation and allocation concealment were explicitly described in only one study. (29) In the remainders, this was absent or unclear. Means of blinding the participants, personnel and outcome assessment were unclear in seven studies, and were only clearly stated in three studies. In one study, 25.5% of the initially recruited participants dropped out prior to randomisation and another 12% following randomisation, (19) and in another study, four subjects were eliminated after randomisation, (30) 
Quantitative meta-analysis
Main effects from the meta-analysis of the nine included studies are summarised in fig. 2 . A detailed description of these results is available in appendix 2.
In adults with ADHD treatment with stimulants (OROS-methylphenidate, IRmethylphenidate, Lis-dexamphetamine, methylphenidate-ER, methylphenidate transdermal system) and atomoxetine had a moderate effect on EL (9 studies, SMD = -0.41; 95% CI: -0.57 to -0.25, z= 5.14, p= 2.7x10 -7 ) and a large effect on ADHD symptoms (9 studies, SMD= -0.8; 95% CI: -1.07 to -0.53, z= 5.85, p= 4.9x10 -9 ). There was evidence of high heterogeneity in both analyses (X 2 = 27.40, I 2 = 70.8%, p= 0.001; X 2 = 72.09, I 2 = 88.9%, p < 0.001, respectively). There was no evidence of publication bias. 
Subgroup analysis
Main effects from the sub-group analyses are shown in table 8.
3.4.1 Outcome measure: In the subgroup analysis of studies using the WRAADDS-EDS as a measure of EL, a higher treatment effect was found for EL symptoms (6 studies, SMD= -0.54; 95% CI: -0.75 to -0.33, z= 5.02, p= 5.2x10 -7 ), compared to the treatment effect of ADHD medication on EL measured by the BRIEF-A (3 studies, SMD= -0.19; 95% CI: -0.33 to -0.05, z= 2.66, p= 0.008).
Medication class:
In the subgroup analysis of stimulants only, a higher effect size was found on EL symptoms (6 studies, SMD= -0.57; 95% CI: -0.80 to -0.34, z= 4.90, p= 9.6x10 -7 ), compared to the small effect of atomoxetine on EL (3 studies, SMD= -0.21; 95% CI: -0.34 to -0.08, z= 3.25, p= 0.001).
We also looked at the effects of stimulants and atomoxetine on core ADHD symptoms. There was a large treatment effect of stimulants on core ADHD symptoms (6 studies, SMD= -0.98; 95 % CI: -1.51 to -0.44, z= 3.58, p= 3.4x10 -4 ) and a moderate to large treatment effect of atomoxetine (3 studies, SMD= -0.57; 95% CI: -0.68 to -0.45, z= 9.76, p= 1.7x10 -22 ).
Medication class and outcome measure:
There was a large treatment effect of stimulants on EL symptoms when the latter was measured by the WRAADDS-EDS (5 studies, SMD= -0.64; 95% CI: -0.91 to -0.36, z= 4.46, p= 8.2x10 -6 ).
Atomoxetine had a small effect on EL when this was measured by the BRIEF-A (2 studies, SMD= -0.15; 95% CI: -0.3 to 0, z= 1.97, p= 0.049). 
DISCUSSION
We conducted a systematic review and meta-analysis examining the efficacy of stimulants (methylphenidate and dexamphetamine/lisdexamfetamine) and atomoxetine on EL in adults.
In addition, we reported on the effects on ADHD symptoms in the same studies to enable a comparison of medication effects on ADHD and EL. Overall we found an effect of stimulants and atomoxetine of d=0.41 (CI: -0.57 to -0.25) for EL symptoms and d=0.8 (CI: -1.07 to -0.53) for ADHD symptoms. Our findings suggest that medications used to treat ADHD also have a significant effect on EL, although the effect appears to be more modest on EL compared to the effect on the core ADHD symptoms of inattention and hyperactivityimpulsivity.
Subgroup analyses indicated that use of the WRAADDS-EDS as an outcome measure might lead to greater estimates of clinical effectiveness of ADHD medications on EL than use of the BRIEF-A-BRI scale. Subgroup analyses also indicated that stimulants might have a stronger effect on reducing EL symptoms than atomoxetine. The greater effects of stimulants compared to atomoxetine on EL is in line with independent findings from meta-analyses of these medication on core ADHD symptoms. (34, 35) Consistent with this, the greatest effect on EL was found when analysing the subgroup of 5 studies which examined the effects of stimulants on EL measured by the WRAADDS-EDS (d=0.64). These findings suggests that the effect sizes on EL found in this meta-analysis may have been affected by measurement bias or differences in the effects of medication class (i.e. stimulants compared to atomoxetine).
In this meta-analysis stimulants and atomoxetine had a two-fold higher treatment effect on core ADHD than on EL symptoms. Nevertheless, the moderate treatment effect shows clinically significant improvement in the symptoms of EL. One study that was included in the qualitative but not the quantitative analysis also found a significant treatment effect of atomoxetine compared with placebo on EL. Patients receiving atomoxetine had a significant reduction of EL symptoms measured by the BRIEF-A self-rated and informant-rated scales. (36) There were a number of limitations associated with this systematic review. First, despite adopting a broad approach towards the selection of studies, many did not meet the eligibility criteria and we were only able to include half of those assessed for eligibility (9 studies) in the meta-analysis. Secondly, there was substantial heterogeneity with regard to patient groups, assessment measures (including differecnes in informant versus self-report vs investigator-rated measures) and quality of studies and we therefore had to use randomeffects models that produced wide confidence intervals. Thirdly, all the studies included in the meta-analysis relied on participants who were selected on the grounds of having high levels of core ADHD symptoms, not EL symptoms and this may have contributed to the differential effect sizes. No studies of stimulants or atomoxetine on EL symptoms were found for conditions other than ADHD, and none of the trials examined the effects of ADHD medication on EL as a primary outcome. Finally, none of the studies reported standard deviation of the change (the difference before and after the intervention) in their effect size calculations (26) and so we had to rely on the pre-treatment standard deviation in our calculations. This may also have contributed to an underestimation of the true effect size associated with EL. (37) Another limitation was in relation to the different duration of the included trials that may have influenced the result on EL. Therefore a meta-regression of trial duration on both ADHD and EL symptoms has been conducted. However, due to the small number of studies and heterogeneity of study characteristic, the results were inadequate.
In conclusion, our findings indicate that EL in patients with ADHD can be treated with stimulants or atomoxetine. Although these medications reduce EL, the effects appear to be modest by comparison with the effects on the core ADHD symptoms of inattention and hyperactivity-impulsivity. Our findings require replication, particularly in patients selected for high baseline levels of EL and addressing methodological issues such as measurement bias and the potential differential effects of stimulants and atomoxetine.
With regard to the clinical implications of our findings, there are two main possibilities to consider. First, that EL reflects a heterogeneous domain of psychopathology that results from a number of distinct processes requiring different treatments, much in the same way there are different causes for fever or headache. In this scenario it would be important to distinguish between stimulant and atomoxetine responsive and non-responsive forms of EL particularly in ADHD. An alternative explanation is that stimulants and atomoxetine may have a more modest effect on EL overall, perhaps indicating the need for additional targeted psychological treatments in some cases. For example, dialectical behaviour therapy has proven efficacy in the treatment of emotional instability in people with borderline personality disorder, (38) and may also have similar effects in ADHD accompanying pharmacological treatments. (39) Further investigations are required using individual patient level data to address these questions.
Finally, we did not find any studies of ADHD drug treatments in adult ADHD patients with comorbid conditions in which emotional symptoms are also prominent. Further studies are therefore required to clarify the role that stimulants or atomoxetine play in the treatment of EL in patients with ADHD and co-occurring conditions such as borderline personality disorder, or bipolar disorder. Notwithstanding, clinicians should be aware that symptoms of EL are often reduced when treating patients with stimluants or atomoxetine who meet diagnostic criteria for ADHD.
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